Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nab-paclitaxel + carboplatin + trastuzumab + pertuzumab
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy regimen consisting of nab-paclitaxel (a solvent-free, human albumin-stabilized formulation of paclitaxel), carboplatin (a platinum-based chemotherapy agent), trastuzumab (a monoclonal antibody targeting HER2), and pertuzumab (a monoclonal antibody that inhibits HER2 dimerization). This regimen is primarily used as neoadjuvant therapy for HER2-positive breast cancer. The combination has demonstrated high pathologic complete response rates in clinical trials with manageable toxicity profiles, though hematological toxicities including anemia and thrombocytopenia have been reported.
- Other names
- PCbHP regimennab-paclitaxel/carboplatin/trastuzumab/pertuzumab
02
Targets
DNAHER2 ECD subdomain II (Human epidermal growth factor receptor 2 dimerization interface)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on nab-paclitaxel + carboplatin + trastuzumab + pertuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nab-paclitaxel + carboplatin + trastuzumab + pertuzumab.